Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Epigenetic Reprogramming in Relapse/Refractory AML

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03263936
Recruitment Status : Recruiting
First Posted : August 28, 2017
Last Update Posted : May 6, 2019
Sponsor:
Information provided by (Responsible Party):
Therapeutic Advances in Childhood Leukemia Consortium

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : July 2020